CELLCEUTIX CORP COM STK USD0.0001 (CTIX)

0.45
0.01 1.58
OTC
Prev Close 0.44
Open 0.45
Day Low/High 0.43 / 0.46
52 Wk Low/High 0.41 / 1.17
Volume 236.57K
Exchange OTC
Shares Outstanding 131.38B
Market Cap 105.10M
Div & Yield N.A. (N.A)

Latest News

Cellceutix Announces Company Name Change To Innovation Pharmaceuticals Inc.

Cellceutix Anti-Cancer Drug Candidate's P53 Activity In Acute Myeloid Leukemia To Be Presented By Independent Researchers At The 2017 European Hematology Association Annual Meeting

Cellceutix Completes Patient Enrollment Of Final Cohort In Phase 2 Trial Of Brilacidin For Inflammatory Bowel Disease; Topline Results Anticipated In July

Cellceutix Provides Corporate Update; Significant Milestones Ahead As Multiple Mid-Phase Clinical Trials Set To Conclude

Cellceutix Announces Details For Upcoming Investor And Shareholder Presentations

Cellceutix CEO Discusses Brilacidin Following Interim Trial Results For Treating Oral Mucositis And Inflammatory Bowel Disease

Cellceutix AACR Poster Presents Data Supporting Kevetrin Modulation Of P53 In Multiple Human Ovarian Cancer Cell-lines And Corresponding Xenograft Tumors

Cellceutix Reports Very Encouraging Interim Analysis Of Phase 2 Drug Candidate Brilacidin For Severe Oral Mucositis (OM) In Head And Neck Cancer Patients; High Potential For Preventative Treatment

Study showed a markedly reduced rate of Severe OM (WHO Grade = 3): Active Arm (Brilacidin): 2 of 9 patients (22.2 percent); Control Arm (Placebo): 7 of 10 patients (70 percent)

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Cellceutix Releases Favorable Topline Findings As Part Of Interim Analysis Of Phase 2 Drug Candidate Brilacidin For The Treatment Of Inflammatory Bowel Disease

Study results, through the first two cohorts of patients treated, support Brilacidin as a novel and promising anti-inflammatory drug candidate

Cellceutix's Phase 2 Drug Candidate Brilacidin Emerging As A Potential Novel Non-Biologic Therapy In Treating Inflammatory Bowel Disease

Study to help guide Cellceutix in continued development of Brilacidin, including planned foam and oral formulations for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn's Disease

Cellceutix Releases Preliminary Efficacy And Safety Data In Interim Analysis Of First Two Cohorts In Phase 2 Trial Of Brilacidin For The Induction Of Remission Of Mild-to-Moderate Ulcerative Colitis

Cellceutix Provides Update On Developing P53 Drug Candidate Kevetrin As An Oral Anti-Cancer Agent

Cellceutix Phase 2 Brilacidin Trial Progresses To Highest Dose Cohort For The Induction Of Remission Of Mild-to-Moderate Ulcerative Colitis

Cellceutix Reports On Q2 Fiscal 2017, Prepares For Important Clinical Milestones

Cellceutix Announces Initiation Of Main Clinical Site For Phase 2a Trial Of P53 Drug Candidate Kevetrin In The Treatment Of Platinum-Resistant/Refractory Ovarian Cancer

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

TheStreet's Adam Feuerstein answers readers' questions about biotech stocks.

Cellceutix Investors See Red Flags in Drug Study

Cellceutix Investors See Red Flags in Drug Study

Does Cellceutix have something to hide?

Cellceutix's Brilacidin Demonstrates Promise In Treating Ulcerative Colitis Supported By Endoscopic Assessment, Patient-Reported Outcomes

Cellceutix's Brilacidin Demonstrates Promise In Treating Ulcerative Colitis Supported By Endoscopic Assessment, Patient-Reported Outcomes

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

CEOs of troubled companies tend to launch public tirades against the 'evil' shorts. The rants are often a smokescreen meant to divert investors' attention from problems.

Cellceutix Completes Enrollment In Second Of Three Planned Cohorts In Phase 2 Clinical Trial Of Brilacidin For Inflammatory Bowel Disease

Cellceutix Completes Enrollment In Second Of Three Planned Cohorts In Phase 2 Clinical Trial Of Brilacidin For Inflammatory Bowel Disease

Cellceutix To Present At Biotech Showcase 2017; Brilacidin For Oral Mucositis Nears Interim Results

Cellceutix To Present At Biotech Showcase 2017; Brilacidin For Oral Mucositis Nears Interim Results

Cellceutix Wishes Shareholders Happy Holidays, Prepares For 2017 Focused On Partnerships

Cellceutix Wishes Shareholders Happy Holidays, Prepares For 2017 Focused On Partnerships

Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites For Oral Prurisol Treatment Of Moderate-To-Severe Psoriasis Initiated And Open For Screening

Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites For Oral Prurisol Treatment Of Moderate-To-Severe Psoriasis Initiated And Open For Screening

Cellceutix Reports Advances In Developing Kevetrin As An Oral Ovarian Cancer Treatment; Company Seeks To Develop World's First P53-Modulating Oral Cancer Drug

Cellceutix Reports Advances In Developing Kevetrin As An Oral Ovarian Cancer Treatment; Company Seeks To Develop World's First P53-Modulating Oral Cancer Drug

Cellceutix Phase 2 Trial Dose Escalates In 2nd Cohort For Brilacidin As A Novel Anti-Inflammatory Drug Candidate For Ulcerative Colitis

Cellceutix Phase 2 Trial Dose Escalates In 2nd Cohort For Brilacidin As A Novel Anti-Inflammatory Drug Candidate For Ulcerative Colitis

Cellceutix Provides Corporate Update And Reports Q1 Fiscal 2017 Financial Results

Cellceutix Provides Corporate Update And Reports Q1 Fiscal 2017 Financial Results

Cellceutix Announces Business Update Call At 10AM Eastern On November 15

Cellceutix Announces Business Update Call At 10AM Eastern On November 15

Management to provide Clinical, Regulatory and Financial Updates

Cellceutix Begins Phase 2b Clinical Trial Of Oral Prurisol In Moderate-to-Severe Chronic Plaque Psoriasis

Cellceutix Begins Phase 2b Clinical Trial Of Oral Prurisol In Moderate-to-Severe Chronic Plaque Psoriasis

Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications

Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications

Load More

From Our Partners

New name for Cellceutix: Innovation Pharmaceuticals
SeekingAlpha

Cellceutix up 17%
SeekingAlpha

Why Investors Are Bullish On Nabriva
SeekingAlpha

Cellceutix: A New Standard Of Care In Oral Mucositis In The Making
SeekingAlpha

Cellceutix's Brilacidin shows encouraging treatment effect in OM patients in mid-stage study; shares ahead 3%
SeekingAlpha

Cellceutix reports encouraging early data from mid-stage study of Brilacidin in UC; shares ahead 4%
SeekingAlpha

Is Criticism Of Cellceutix Pipeline Or Business Plan Warranted? A 2-Fold Evaluation
SeekingAlpha

Cellceutix commits to mid-stage study of Kevetrin in ovarian cancer
SeekingAlpha

Cellceutix Corp reports FQ2 results
SeekingAlpha

TheStreet's Feuerstein says Cellceutix latest example of value of scrutinizing attacks on "evil" short sellers; shares off 4%
SeekingAlpha

Cellceutix: when a CEO rants about 'criminal' short sellers, smart investors see red flags
SeekingAlpha

Cellceutix takes issue with Mako's latest bearish report
SeekingAlpha

Cellceutix: Financing Partners Arrested For Alleged Ponzi Scheme, Company Faces Risk Of Death Spiral Liquidity Crunch
SeekingAlpha

Cellceutix (CTIX) presents at Biotech Showcase San Francisco
SeekingAlpha

New Oral Psoriasis Drug Tops Cellceutix Catalysts
SeekingAlpha

Watchlist

Trending
Sears CEO Eddie Lampert Looks Like He Is Sucking Company Dry
Should You Invest In DowDuPont Now?
Dow Makes Move Higher as Bond Yields Hover Near 3% Threshold
Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters
Why the Stock Market Won't Crash When 10-Year Yields Smash Through 3%